Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XBD173 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| XBD173 | DRUG | - |
Inclusion Criteria: * Current doctor's diagnosis of generalized anxiety disorder * In need of psychiatric treatment * Willingness to complete all aspects of the study Exclusion Criteria: * Current doctor's diagnosis of major depression * History of schizophrenia or schizoaffective disorders * Dru...
XBD173 is an investigational small molecule being developed for the treatment of anxiety disorders, specifically generalized anxiety disorder. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
XBD173 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The company is conducting clinical trials to evaluate the drug's efficacy and safety in patients with anxiety disorders.
XBD173 is in Phase 2 clinical development. It has completed one Phase 2 trial, which was a randomized, double-blind study in patients with generalized anxiety disorder. The drug remains investigational and has not received regulatory approval.
XBD173 has been studied in one completed Phase 2 clinical trial, identified as NCT00108836. This trial evaluated the efficacy, safety, and tolerability of XBD173 in patients with generalized anxiety disorder, enrolling 400 participants across the United States and Canada.
No, XBD173 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for anxiety disorders. The completed clinical trial was not designed to support approval, and further studies would be needed to establish its safety and efficacy.